Global Stem Cell Therapy Market by Treatment Mode (Autologous & Allogeneic), Therapeutic Applications (CNS, CVS, GIT, Wound Healing, Musculoskeletal, Eye, & Immune System) - Forecasts to 2020
DUBLIN, May 12, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/sqctb8/stem_cell_therapy) has announced the addition of the "Stem Cell Therapy Market by Treatment Mode (Autologous & Allogeneic), Therapeutic Applications (CNS, CVS, GIT, Wound Healing, Musculoskeletal, Eye, & Immune System) - Regulatory Landscape, Pipeline Analysis & Global Forecasts to 2020" report to their offering.
http://photos.prnewswire.com/prnh/20130307/600769
The global stem cell therapy market on the basis of the mode of treatment is segmented into allogeneic and autologous stem cell therapy. The allogeneic stem cell therapy is expected to command the largest share of the market in 2015, and is also expected to grow at a higher CAGR than autologous therapies from 2015 to 2020. Based on the therapeutic applications, the global market is segmented into eye diseases, metabolic diseases, GIT diseases, musculoskeletal disorders, immune system diseases, CNS diseases, CVS diseases, wounds and injuries, and others.
A number of factors such as increasing funding from government and private organizations, growing industry focus on stem cell research, and increasing global awareness about stem cell therapies through various organizations are driving the growth of the global market. Furthermore, increasing funding for new stem cell lines, development of advanced genomic methods for stem cell analysis, and rising approvals of clinical trials for stem cells therapy are other factors that are propelling the growth of the market. In addition, increasing stem cell researches in developing markets, emergence of the induced pluripotent stem (iPS) cells as an alternative to ESCs, and the evolution of novel stem cell therapies unfolds new avenues for the growth of this market.
However, a few pivotal factors such as lack of required infrastructure (especially in emerging nations), ethical issues related to embryonic stem cell, and difficulties related with the preservation of stem cell are hindering the growth of this market. Moreover, dearth of reimbursements and high costs incurred in stem cell processing are the foremost challenges faced by the industry players.
The global stem cell market in 2015is expected to be dominated by North America, followed by Asia-Pacific and Europe. However, Asia-Pacific market is expected to surpass North America by 2020, owing to the high number of ongoing research activities. Over the next five years, the growth of the market in the Asia-Pacific region is likely to be centered in Japan, South Korea, China, and India. A number of factors such as the increasing regulatory support through favourable government policies, strong product pipelines, increasing licensing activities, and growing focus of both international and domestic players on the Asia-Pacific stem cell therapy market pose as the key drivers to the growth of market.
Key Topics Covered:
1 INTRODUCTION
2 EXECUTIVE SUMMARY
3 MARKET DYNAMICS
4 PIPELINE ANALYSIS
5 INVESTOR NETWORK
6 GLOBAL STEM CELL THERAPY MARKET, BY MODE OF THERAPY
7 GLOBAL STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATIONS
8 REGULATORY LANDSCAPE
9 GLOBAL STEM CELL THERAPY MARKET, BY GEOGRAPHY
10 COMPETITIVE LANDSCAPE
11 COMPANY PROFILES
Companies Mentioned:
- Aastrom Biosciences Inc.
- Advanced Cell Technologies Inc.
- Athersys Inc.
- Celgene Corporation
- Cellular Dynamics International
- Cytori Therapeutics Inc.
- Fibrocell Science Inc.
- Gamida Cell Ltd.
- Mesoblast Ltd.
- Pluristem Therapeutics Inc.
- StemCells Inc.
For more information visit http://www.researchandmarkets.com/research/sqctb8/stem_cell_therapy
Media Contact: Laura Wood, +353-1-481-1716, press@researchandmarkets.net
Share this article